-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Preparing for Personalized Care in Myelodysplastic Syndromes: Integrating Innovative Treatments Into a Cohesive Patient Care Model

Sponsor: educational grants from Agios Pharmaceuticals, Inc., Astex Pharmaceuticals, Inc., Bristol Myers Squibb, Taiho Oncology, Inc., and Takeda Oncology
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
Diseases, Therapies, MDS, Adverse Events, Biological Processes, Cell Lineage, Myeloid Malignancies, Clinically relevant
Friday, December 4, 2020: 7:00 AM-10:00 AM
Steven D. Gore, MD, National Cancer Institute
Gore: Abbvie: Consultancy, Honoraria, Research Funding.
Michael R. Savona, MD, Vanderbilt University Medical Center , David A. Sallman, MD, H. Lee Moffitt Cancer Center and Prapti Patel, MD, Harold C Simmons Comprehensive Cancer Center
Sallman: Agios, Bristol Myers Squibb, Celyad Oncology, Incyte, Intellia Therapeutics, Kite Pharma, Novartis, Syndax: Consultancy; Celgene, Jazz Pharma: Research Funding. Patel: France Foundation: Honoraria; Celgene: Consultancy, Speakers Bureau; Agios: Consultancy; DAVA Pharmaceuticals: Honoraria.
This CE activity has been developed in collaboration with Aplastic Anemia and MDS International Foundation.

Myelodysplastic syndromes (MDS) are a group of clonal myeloid neoplasms characterized by reduced and/or defective production of red blood cells, platelets, and mature granulocytes, often resulting in anemia, bleeding, increased risk of infection, and risk of transformation to AML. For many years, supportive therapy, blood transfusion, erythropoiesis-stimulating agents, and treatment of infections were the only therapies available. Subsequently, DNA methyltransferase inhibitors and immunomodulators showed survival benefits in MDS, leading to additional research on the efficacy of novel erythroid maturation agents in the setting of MDS-related anemia. Currently, multiple innovative therapies—including multikinase inhibitors, NEDD8-activating enzyme inhibitors, isocitrate dehydrogenase 1/2 inhibitors, BCL-2 inhibitors, and CD47 antibodies—are being investigated to improve care across different MDS populations, including low-, intermediate-, or high-risk patients, elderly individuals with comorbid conditions, and those ineligible for intensive treatment.

In this CME web broadcast, an expert panel will discuss the diagnosis and management of MDS. The panelists will review innovative treatment strategies, prognostic scoring systems for risk stratification, and how hematologist-oncologists can recommend appropriate therapeutic options for patients with MDS.

See more of: Satellite Symposia